In vitro pharmacological profile of Compound A

Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.

In vivo PK/PD profile of Compound A

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.

Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need

Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!

Lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation

Get to know more about lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation!

Mouse models of hepatocellular carcinoma

Get to know more about our comprehensive & functional preclinical platform for immunotherapy research using mouse models (PDX, human transgenic mouse).

Using individual or a consortium of bacteria for immuno-oncology research

Get to know more about the beneficial role of bacteria for cancer therapy. Oncodesign Services, vector Of Innovation in oncology, inflammation & Covid-19.

[EN] How to Better Optimize an Oncology Drug Discovery Program

Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...

PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells

Recent advances in the field of immuno-oncology demonstrate the beneficial immunostimulatory effects of the induction of immunogenic cell death (ICD).

Scientific Posters | AACR 2022

Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)

Development of small macrocyclic kinase inhibitors

Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services

Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.